Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
KING OF PRUSSIA, Pa., March 02, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 8, 2017 at 8:00 am EST to review financial results as of and for the year ended December 31, 2016 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 81728820).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 81728820). Following the conclusion of the call, the webcast will be available for replay for 30 days.
Separately, the Company will be webcasting its corporate presentation at the Cowen 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. EST in Boston. This presentation will include discussion of how recently-reported data support the Company’s plans for regulatory approval and subsequent commercialization of OLINVO™ (oliceridine injection) in the U.S.
To join a live audio webcast of the Cowen presentation, please visit the Investor Presentation section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734 for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
